

Edgar Filing: Spark Therapeutics, Inc. - Form 8-K

Spark Therapeutics, Inc.  
Form 8-K  
May 31, 2018

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of The Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): May 30, 2018

Spark Therapeutics, Inc.  
(Exact name of registrant as specified in its charter)

Delaware                      001-36819      46-2654405  
(State or other jurisdiction   (Commission   (IRS Employer  
of incorporation)              File Number)   Identification No.)

3737 Market Street  
Suite 1300    19104  
Philadelphia, PA  
(Address of principal executive offices)      (Zip Code)

Registrant's telephone number, including area code: (888) 772-7560  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: Spark Therapeutics, Inc. - Form 8-K

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

Item 5.07. Submission of Matters to a Vote of Security Holders

On May 30, 2018, Spark Therapeutics, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Meeting”), at which a quorum was present. At the Meeting, the stockholders of the Company voted on the following three proposals:

1. The following nominees were elected to the Company’s Board of Directors (the “Board”) as Class III directors for terms expiring at the 2021 annual meeting of stockholders. The votes cast at the Meeting were as follows:

• On the election of Jeffrey D. Marrazzo as a Class III director - 23,866,594 shares voted for and 7,106,441 shares withheld.

• On the election of Vincent J. Milano as a Class III director - 22,599,997 shares voted for and 8,373,038 shares withheld.

• On the election of Elliott Sigal, M.D., Ph.D. as a Class III director - 23,792,236 shares voted for and 7,180,799 shares withheld.

There were 2,656,800 broker non-votes for this proposal.

2. A non-binding, advisory proposal on the compensation of the Company’s named executive officers was approved. The votes cast at the Meeting were as follows: 30,411,199 shares voted for, 553,339 shares voted against and 8,497 shares abstained. There were 2,656,800 broker non-votes for this proposal.

3. The appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2018 was ratified. The votes cast at the Meeting were as follows: 33,574,992 shares voted for, 44,330 shares voted against and 10,513 shares abstained. There were zero broker non-votes for this proposal.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SPARK  
THERAPEUTICS,  
INC.

Date: May 31, 2018

By: /s/ Joseph W.  
La Barge  
Joseph W. La  
Barge  
General  
Counsel